William Oliver Tobin, M.B., B.Ch., B.A.O., Ph.D.

The purpose of this study is to evaluate, jointly and independently among patients deemed at higher risk vs. lower risk for disability accumulation, whether an "early aggressive" therapy approach, versus starting with a traditional, first-line therapy, influences the intermediate-term risk of disability, and to evaluate if, among patients deemed at lower risk for disability who start on first-line MS therapies but experience breakthrough disease, those who switch to a higher-efficacy versus a new first-line therapy have different intermediate-term risk of disability.FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early aggressive therapy with respect to preventing long-term disability. The infectious risks and other complications associated with higher-efficacy treatments highlight the need to quantify their effectiveness in preventing disability. The TRaditional versus Early Aggressive Therapy for MS (TREAT-MS) trial is a pragmatic, randomized controlled trial that has two primary aims:

The purpose of this study is to gain an understanding of the progressive multiple sclerosis (MS) experience and the meaning patients bring to the experience. By learning about the specific care gaps, barriers, and overall scope of burden, we hope to assess how telemedicine may be effectively used to improve the patient experience and management of progressive MS. 

The purpose of this study is to determine clinical outcome following treatment for multiple sclerosis (MS) relapse, in patients who were seen at Mayo Clinic.